Low-Dose ASA Risks Outweigh Benefits in Younger Women

This article originally appeared here.
Share this content:
Low-Dose ASA Risks Outweigh Benefits in Younger Women
Low-Dose ASA Risks Outweigh Benefits in Younger Women

FRIDAY, Dec. 5, 2014 (HealthDay News) -- For women younger than 65, taking low-dose aspirin for years lowers the risks of heart attack, stroke, and colorectal cancer by a small amount, but the benefit is countered by an increase in the risk of major gastrointestinal bleeding, according to a study published online Dec. 4 in Heart.

The findings are based on a clinical trial of 27,939 women who were largely healthy and relatively young -- about 55 years old, on average, at the start of the study. They were randomly assigned to take low-dose (100 mg) aspirin or placebo pills every other day. Over the next 15 years, about 11 percent of the women either developed cancer, suffered a heart attack or stroke, or died of cardiovascular causes.

Women who'd taken aspirin saw a small decrease in their odds of cardiovascular disease or colorectal cancer -- but at the expense of an increase in the risk of gastrointestinal bleeding, the researchers found. That expense was clear among women younger than 65. The researchers estimate that for every 133 women on aspirin for 15 years, one would suffer a major gastrointestinal bleeding episode -- serious enough to warrant a hospital stay. And one out of 29 women would have less serious problems: a stomach ulcer or slight bleeding in the digestive tract. By comparison, 709 women would have to take aspirin to prevent one case of colorectal cancer, and 371 would have to regularly take the drug to ward off one cardiovascular complication.

The picture changed, however, as women grew older. Among those age 65 and up, 29 would need to take aspirin, long term, to prevent one case of cardiovascular disease or cancer.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »